SLC5A2 and hydrops fetalis: Recent CV outcome trials (CVOTs) have identified newer therapeutic agents with CV benefits, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors reducing hospitalization for HF and glucagon-like peptide-1 (GLP-1) receptor agonists reducing major adverse CV events (MACE), albeit with inconsistent effects on HF outcomes (70).